Women's 40+: baseline blood test panel for preventive checkup

At 40, physiological shifts are already under way in a woman’s body — often quietly, for years. Oestrogen levels begin to fluctuate and gradually decline long before the final menstrual period. Bone mass decreases by approximately 1% per year in the premenopausal years and accelerates to around 2% per year in the first five years after menopause — the most critical window of loss. Cardiovascular risk, which is lower in women of reproductive age than in men of the same age, catches up and surpasses male risk roughly ten years after menopause.

None of these processes announces itself with pain or an obvious symptom — until it becomes clinically significant. That is why lab tests at 40 are not about checking everything at once, or about anxiety. They are about establishing a personal reference point. An LDL of 3.4 mmol/L at 40 and the same value at 46 are two entirely different situations, depending on whether that number has been rising or holding steady over the intervening years.

This article outlines the baseline screening panel for women around the age of 40, aligned with USPSTF, NICE, NAMS, NOF, and ACOG recommendations. For each test — a brief explanation of what it is asking and what conversation it opens with your doctor.

Baseline panel for women 40+

No doctor orders everything at once — priorities depend on your risk factors, symptoms, and prior results. But the following covers the minimum across the key hormonal, metabolic, and bone domains.

Test	What it screens for	Recommended frequency
Lipid panel (TC, LDL, HDL, TG)	Cardiovascular risk	Every 4–6 years (more often with risk factors)
HbA1c or fasting glucose	Type 2 diabetes / prediabetes	Every 3 years from age 35
Blood pressure (clinic)	Hypertension	Annually
TSH	Thyroid dysfunction	Every 5 years from age 35 (ATA); more often with symptoms
Anti-TPO antibodies	Autoimmune thyroiditis	If TSH is elevated, or before planned pregnancy
FSH + estradiol	Menopausal status (on indication)	NOT routine in women > 45 (NICE); only when diagnosis is uncertain
Calcium + PTH + 25(OH)D	Bone metabolism	Once at baseline; repeat if abnormal
Creatinine + eGFR	Kidney function	Annually with risk factors; otherwise every 2–3 years
CBC + ferritin	Anaemia, iron deficiency	Annually (especially with heavy periods)
Vitamin B12	Deficiency (metformin, vegetarian diet, gastritis)	Once at baseline after 40; repeat if abnormal

Most of these tests can be drawn in a single venous blood sample as part of a standard comprehensive panel. The logistics are minimal; the information yield is high.

Hormonal screening: when and why to measure FSH/LH/estradiol

NICE NG23 is explicit: for women over 45 with typical menopausal symptoms — irregular periods, hot flushes, night sweats, mood changes — FSH and LH testing is not required to establish the diagnosis. Menopause is a clinical assessment. Routine measurement in this group does not change management and only complicates interpretation due to the natural variability of hormone levels across the cycle and menopausal transition.

FSH and LH testing is justified in the following situations:

suspected premature menopause (before age 40) or premature ovarian insufficiency (POI)
differential diagnosis of amenorrhoea
women under 45 without typical symptoms, where the diagnosis is not straightforward
monitoring the effect of hormone replacement therapy in specific clinical scenarios

Estradiol and LH levels vary significantly across the menstrual cycle; a single measurement without clinical context is rarely interpretable on its own. For detailed reference ranges for FSH and LH across cycle phases and the menopausal transition — see FSH and LH in menopause. For estradiol reference ranges across follicular, ovulatory, and luteal phases — see the dedicated E2 article.

Thyroid: TSH + anti-TPO antibodies

Hypothyroidism occurs five to ten times more frequently in women than in men, and its prevalence increases with age. Subclinical hypothyroidism — elevated TSH with normal free T4 and no symptoms — is diagnosed in approximately 5–10% of women over 40.

Screening strategy:

TSH is the first step. The American Thyroid Association recommends a baseline TSH from age 35, repeated every five years; more frequently with symptoms, autoimmune conditions, or a relevant family history.
Anti-TPO antibodies are the second step — if TSH is elevated. Positive anti-TPO confirms autoimmune Hashimoto’s thyroiditis and predicts progression to overt hypothyroidism.
Routine anti-TPO measurement when TSH is normal and there are no symptoms is not recommended, except when planning a pregnancy.

For TSH reference ranges and the clinical approach to abnormal results — see TSH: the thyroid function test explained. For the role of antibodies and autoimmune thyroiditis — see Anti-TPO antibodies.

Bone metabolism and osteoporosis risk

Osteoporosis is one of the most underestimated screening blind spots in women over 40. Accelerated bone resorption driven by oestrogen deficiency begins in perimenopause and peaks in the first years after menopause — well before a standard DEXA scan shows a T-score of −2.5 or below.

DEXA recommendations:

NOF (National Osteoporosis Foundation): routine DEXA for all women from age 65
Earlier — when risk factors are present: early menopause (before 45), low BMI (below 20), prolonged corticosteroid use, a history of low-trauma fractures, or a hip fracture in the mother

The laboratory minimum for assessing bone metabolism is calcium + 25(OH)D + PTH. Vitamin D deficiency — particularly below 30 nmol/L — is the most common reversible cause of secondary hyperparathyroidism and accelerated bone resorption. For a detailed breakdown — see Calcium, PTH, and bone health and Vitamin D: levels and deficiency.

Metabolic health (lipid panel + HbA1c)

Before menopause, oestrogen exerts a cardioprotective effect: it raises HDL and lowers LDL. After menopause this protection disappears — LDL rises, HDL falls, and triglycerides increase. Cardiovascular risk in postmenopausal women converges with that of men of the same age, and roughly ten years post-menopause it exceeds it.

The lipid panel is not interpreted in isolation — it is evaluated together with the 10-year ASCVD risk calculated using the AHA/ACC Pooled Cohort Equations. A baseline measurement at 40 creates the reference point that all future results will be compared against.

USPSTF recommends screening for prediabetes and type 2 diabetes in adults aged 35–70 who are overweight or obese (Grade B). HbA1c is practical in this context because it requires no strict fasting and reflects average glucose over two to three months.

For a full breakdown of lipid panel components — see LDL and HDL cholesterol. For prediabetes criteria and HbA1c interpretation — see HbA1c: what the result means for diabetes and prediabetes. Insulin resistance can precede a rise in blood glucose by years; fasting insulin and HOMA-IR are additional markers used for specific clinical indications (for example, PCOS work-up), not as routine screening.

Hematology and deficiencies (CBC + ferritin)

Iron deficiency is the most common nutritional deficiency among women of reproductive age. Heavy menstrual bleeding — which often appears or worsens in perimenopause due to anovulatory cycles — is the primary risk factor.

Practical approach:

Before menopause: annual CBC + ferritin, particularly with heavy periods or symptoms such as fatigue, breathlessness, or poor exercise tolerance.
After menopause: CBC on clinical indication; new-onset iron deficiency anaemia warrants investigation to exclude gastrointestinal bleeding.

Vitamin B12 and folate are worth checking at baseline after 40 — particularly with a vegetarian or vegan diet, metformin use, chronic atrophic gastritis, or relevant symptoms (numbness, tingling, cognitive fatigue). Neurological symptoms of B12 deficiency can precede anaemia, and late treatment can leave irreversible damage. Prolactin and insulin/HOMA-IR are not part of routine screening; they are measured on specific clinical indication.

For reference ranges and interpretation — see CBC: what your blood count results mean and Ferritin: iron stores and deficiency.

What does NOT belong in routine screening

Not everything sold as a “women’s panel” reflects evidence-based screening. USPSTF and international gynaecological bodies do not recommend the following without specific clinical indications:

CA-125 for ovarian cancer screening — USPSTF Grade D recommendation (harms exceed benefits due to a high rate of false positives leading to unnecessary invasive procedures)
AMH in women over 40 — levels are typically already low; without IVF planning, the result carries no actionable clinical meaning
Routine prolactin without symptoms (galactorrhoea, amenorrhoea, persistent anovulatory cycles) — interpretation requires correct pre-test preparation and clinical context
Isolated estradiol without FSH — without clinical context it cannot be meaningfully interpreted
Routine homocysteine — screening is not recommended without cardiovascular indications

If these tests appear in a “package” without a discussion of your specific situation, it is worth asking your doctor about the rationale.

Family history: when to screen earlier or more often

Family history is not a source of anxiety — it is a clinical variable. It shifts screening earlier and increases frequency; it does not change which markers you test.

Situation	Action
Hip fracture in mother or sister	DEXA earlier (from age 50+, not 65)
Early menopause in mother (before 45)	Follow your own symptoms; consider FSH when diagnosis is uncertain
Breast or ovarian cancer in a first-degree relative	Separate consultation with a breast specialist or geneticist; consider BRCA screening
T2DM in a parent or sibling	HbA1c from age 35, not 45
Autoimmune thyroid disease in the family	TSH + anti-TPO earlier and more frequently

How HealthLab helps track trends

The multi-domain profile of a woman at 40 — hormones, thyroid, bone metabolism, cardiovascular risk — is most valuable not as a one-off snapshot but as a trend over time. A TSH that has crept from 1.8 to 3.5 mIU/L over three years, with stable anti-TPO, is an entirely different clinical picture from an isolated result of 3.5.

HealthLab automatically recognises biomarkers from PDF lab reports issued by any laboratory — TSH, FSH, calcium, vitamin D, LDL, HbA1c, ferritin — and builds a trend chart over time with reference range overlays. No manual data entry, no spreadsheets.

Download HealthLab on the App Store

Frequently asked questions

Do I need to check hormones every year if I'm 42 and have no symptoms?

No. Routine annual measurement of FSH, LH, or estradiol without symptoms is not recommended. NICE NG23 explicitly advises against using these tests as screening tools in women over 45 — menopause is a clinical diagnosis. If you do have symptoms — irregular cycles, hot flushes, sleep disruption, mood changes — discuss with your doctor whether laboratory confirmation is warranted in your specific case.

When should I have a DEXA bone density scan?

NOF recommends routine DEXA for all women from age 65. Earlier testing is appropriate when risk factors are present: early menopause (before 45), low BMI (below 20), prolonged corticosteroid use, a history of low-trauma fractures, or a hip fracture in your mother. If several risk factors are present simultaneously, a DEXA conversation is reasonable from age 50–55. The laboratory minimum before DEXA: calcium + 25(OH)D + PTH, to rule out secondary causes of bone loss.

Do I need CA-125 ovarian cancer screening every year?

No. USPSTF assigns CA-125 screening in asymptomatic women a Grade D rating — meaning harms outweigh benefits. The core problem: CA-125 generates many false positives (it rises with endometriosis, fibroids, inflammation, and even menstruation), leading to unnecessary surgical procedures and significant anxiety. If you have a first-degree relative with ovarian or breast cancer, discuss this with your doctor separately — the strategy in that setting is different.

Do I need to fast before this baseline panel?

It depends on the specific tests. A lipid panel and fasting glucose require the standard 9–12 hour fast (water is fine). HbA1c does not require fasting, but since it is usually ordered alongside lipids, a single early-morning fasting draw covers everything conveniently. TSH, FSH, calcium, and ferritin are not meaningfully affected by food intake, but drawing them together in the same fasting morning session is the most practical approach. If insulin or HOMA-IR is also being measured, fasting is mandatory.

This material does not replace clinical advice. Interpreting laboratory results always requires clinical context.